International Stem Cell Corp to Sell Lifeline Cell Technology for $25M, Transforming Cash Position
ISCO has more than doubled off its 52-week low of $0.056 on light trading volume (0.3× avg).
Summary
International Stem Cell Corp agreed to sell its Lifeline Cell Technology subsidiary for $25 million, a deal valued at nearly 19x its market cap, providing a lifeline to the cash-strapped company.
Key Events · M&A and Partnerships · ISCO
-
Subsidiary Sale Agreement Signed
Entered into a Membership Interest Purchase Agreement on July 10, 2026, to sell 100% of Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. for $25.0 million, subject to working capital and other adjustments.
-
Transformative Financial Impact
The $25 million purchase price is approximately 19 times the company's current market capitalization of $1.3 million, providing immediate and substantial liquidity to address going-concern risks.
-
Escrow and Holdback Provisions
$2.5 million of the purchase price will be held in an indemnity escrow for nine months post-closing, with $1.5 million released after six months; an additional $100,000 adjustment escrow is also established.
-
Closing Conditions and Timeline
Closing is expected in Q3 2026, subject to stockholder approval (requisite holders already signed support agreements), SEC information statement clearance, and other customary conditions.
Analysis · ISCO · Life Sciences
International Stem Cell Corp, a micro-cap life sciences company with a going-concern warning and a market cap of just $1.3 million, has agreed to sell its subsidiary Lifeline Cell Technology for $25 million in cash. The purchase price is nearly 19 times the company's entire market value, representing a transformative liquidity event. The deal includes a $2.5 million indemnity escrow and a $100,000 adjustment escrow, with closing expected in Q3 2026. This sale directly addresses the company's existential cash crisis, providing a clear path to resolving its going-concern uncertainty and potentially returning significant value to shareholders.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ISCO was trading at $0.17 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.06 to $0.27. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.